Humanized vs. Fully Human Antibodies: What’s the Difference?

1. Humanized vs. Fully Human: The Core Difference

Antibodies are proteins designed to recognize and neutralize specific targets (antigens). But when antibodies are derived from non-human species, such as mice, they can trigger unwanted immune responses in patients.

• Humanized antibodies are originally non-human antibodies in which only the antigen-binding loops (CDRs) is grafted onto a human framework. They are mostly human (>90%), with some residual non-human sequences.
• Fully human antibodies come from human genetic material or repertoires from the start (transgenic mice with human loci, phage display libraries built from human sequences, or B cells from human donors). These approaches minimize the risk of immunogenicity and often improve clinical tolerance.

2. When to Use Humanized vs. Fully Human Antibodies

Humanized antibodies:

• Best when you already have a validated non-human antibody.
• Useful for transitioning proven research tools into therapeutic candidates

Fully human antibodies:

• Preferred for de novo discovery in therapeutic programs.
• Lower immunogenic risk, higher clinical acceptance.
• Especially relevant in long-term or chronic treatments.

3. Methods to Obtain Humanized or Fully Human Antibodies

Transgenic (Humanized) Mice & Single B-Cell Technologies

Humanized mice are genetically engineered to carry human immunoglobulin gene loci. After being immunized with a target antigen, they produce fully human antibodies that are harvested.  Transgenic mice are genetically engineered to carry human immunoglobulin gene loci. After being immunized with a target antigen, they generate human B cells that can be harvested for antibody discovery. These B cells, can then be screened at the single-cell level to recover antibodies targeting clinically relevant epitopes with precision.

Advantages:

The key advantage of this approach is that the antibodies benefit from natural in vivo affinity maturation, which results in molecules with high specificity and favorable biophysical properties, closely resembling those of approved drugs. Because the antibodies are entirely human in sequence, the risk of immunogenicity is very low, making them well suited for therapeutic use. Another strong benefit is that the process does not require a separate humanization step, saving valuable time and effort in development. It is no coincidence that many blockbuster therapeutics, including Humira®, Dupixent®, Repatha®, and Praluent®, were generated using this method.

Limitations: 

However, the limitations should not be overlooked. The reliance on animals introduces ethical and regulatory considerations that require specialized infrastructure, time, and approvals, often making the process slower and more expensive compared to in vitro alternatives. Single B cell workflows also require advanced instrumentation, bioinformatics, and highly precise handling. Additionally, this approach is less effective for developing antibodies against self-antigens or highly conserved targets, where the immune response of the mouse may be limited.

See ProteoGenix Humanized Mice solutions

See ProteoGenix Single B Cell services

Phage Display 

Human Libraries

Phage display is an entirely in vitro method that relies on expressing human antibody gene fragments on the surface of bacteriophages. High-affinity binders are then isolated through a process known as biopanning, which enables screening from very large and diverse libraries that can reach up to 10¹¹ variants.

Advantages: 

This technique offers significant advantages, particularly in terms of speed and scalability. Because it bypasses the need for immunization or animal models, researchers can rapidly identify binders against virtually any target, including toxic molecules or antigens that fail to trigger a strong immune response in vivo. This makes phage display an especially valuable tool for urgent applications, such as rapid lead generation during outbreak responses.

Limitations: 

Yet, the method also comes with limitations. Since it lacks the natural affinity maturation provided by an immune system, additional engineering steps are often required to optimize the binders. The antibodies recovered are frequently in fragment formats such as scFvs, which must be converted into full-length molecules before therapeutic use. Although in vitro maturation strategies exist, they add complexity and time to the process.

ProteoGenix goes one step further by offering the world’s first cancer-focused human antibody library, specifically designed to accelerate the discovery of next-generation therapeutics.

Discver our Cancer Antibody Library

Non-Human Libraries

Beyond human repertoires, phage display can also be performed with non-human libraries, including murine, camelid, and synthetic antibody repertoires. These systems broaden the structural diversity of the antibodies and can provide unique properties that are difficult to obtain with human sequences alone.  

Advantages: 

The main advantage of non-human libraries is their ability to expand the discovery space and generate antibodies with novel frameworks. Camelid-derived single-domain antibodies, also known as nanobodies, are exceptionally small and stable, giving them access to cryptic epitopes that conventional antibodies cannot reach. Synthetic libraries further enhance this potential by introducing targeted diversity into specific regions of the antibody, allowing for tailored solutions against particularly challenging antigens. This makes non-human libraries a powerful tool when innovative formats or unusual binding properties are required.  

Limitations: 

Despite their strengths, these approaches still carry limitations. Because the sequences are non-human in origin, antibodies derived from these libraries usually require a subsequent humanization step to reduce immunogenicity, adding time and complexity to the workflow. In addition, while synthetic libraries offer extensive diversity, they cannot fully replicate the natural pairing and maturation processes of an immune system, which sometimes results in binders that need further optimization to improve affinity, stability, or overall developability.  

Explore ProteoGenix Phage Display Libraries

CDR Grafting (Humanization)

When a murine antibody already exists, humanization can be performed by grafting the antigen-binding complementarity-determining regions (CDRs) onto a human antibody framework.

Advantages: 

The benefit of this strategy lies in its ability to preserve antigen specificity while simultaneously lowering the risk of immunogenicity, since the resulting molecule can often achieve more than 90% human sequence identity. It is particularly valuable when researchers are working with legacy murine antibodies or validated preclinical leads that have already demonstrated promising results.

Limitations: 

The approach, however, is not without drawbacks. The grafting process can sometimes lead to a loss of affinity or functional activity, requiring extensive back-mutations or structural optimization to restore performance. Furthermore, because the CDRs remain murine in origin, there is still a residual risk that patients may develop anti-drug antibodies, which can impact safety or efficacy during clinical use.

Go to ProteoGenix Humanization Solution

4. How to Choose the Right Method

Your choice depends on several factors:

• Antigen type: toxic, conserved, or self-antigens may favor phage display or B cell methods.
• Starting point: 
  • Existing non-human antibody = humanization
  • No existing lead = transgenic mice or phage display.
• Timeline and budget: Most screening methods (phage display, single B cell) are relatively fast. The main factor that extends project timelines is the need for animal immunization. Since it is required for humanized mice projects, timelines naturally become longer and costs higher.
• Clinical goal: for first-in-class therapeutics, fully human is usually preferred; whereas for optimized legacy antibodies, humanization can be the best route.

5. Antibody Development at ProteoGenix

At ProteoGenix, we support every stage of antibody generation:

• Fully human discovery via transgenic mice, phage display, and single B cell technologies.
• Humanization of non-human antibodies using advanced CDR grafting and optimization workflows.

Our expertise allows us to tailor the best strategy to your antigen, therapeutic goals, and timeline. Importantly, we take into account the inherent limitations of each method, whether that means optimizing affinity after CDR grafting, complementing phage display with in vitro maturation, or implementing streamlined processes to reduce the timelines and costs of animal-based approaches. This way, we ensure your project benefits from the strengths of each technology while minimizing potential drawbacks.

Contact our team to discuss your antibody project

Bibliography

Almagro, J. C., Pedraza-Escalona, M., Arrieta, H. I., & Pérez-Tapia, S. M. (2019). Phage display libraries for antibody therapeutic discovery and development. Journal of Biomedical Science, 26, Article 31. https://doi.org/10.1186/s12929-019-0592-z

Carter, P. J., & Lazar, G. A. (2021). Next generation antibody drugs: Pursuit of the “high-hanging fruit.” Nature Reviews Drug Discovery, 20(5), 354–355. https://doi.org/10.1038/s41573-021-00175-8

Chen, H., et al. (2022). AI in antibody discovery. Frontiers in Bioinformatics, 2, Article 1044975. https://doi.org/10.3389/fbinf.2022.1044975

Ecker, D. M., Jones, S. D., & Levine, H. L. (2015). The therapeutic monoclonal antibody market. mAbs, 7(1), 9–14. https://doi.org/10.4161/19420862.2015.989042

Else, H. (2018). The AI scientist’s dilemma. Nature Index, 557, 5–6. https://doi.org/10.1038/d42473-018-00011-5

GETAID. (s.d.). Fiche médicament : Adalimumab (Humira®). Groupe d’Étude Thérapeutique des Affections Inflammatoires du tube Digestif. https://www.getaid.org/fiches-medicament/ladalimumab-humira

Green, M. R., & Sambrook, J. (2009). Molecular cloning: A laboratory manual (4th ed.). Nature Protocols, 4(1), 68–77. https://doi.org/10.1038/nprot.2009.3

Kaplon, H., & Reichert, J. M. (2016). Antibodies to watch in 2016. mAbs, 8(1), 197–204. https://doi.org/10.1080/19420862.2015.1125583

Kaplon, H., Muralidharan, M., Schneider, Z., & Reichert, J. M. (2023). Antibodies to watch in 2023. mAbs, 15(1), e2150678. https://doi.org/10.1080/19420862.2022.2150678

Kaplon, H., & Reichert, J. M. (2021). Antibodies to watch in 2021. mAbs, 13(1), 1924347. https://doi.org/10.1080/19420862.2021.1924347

Lee, J. H., et al. (2024). Novel therapeutic antibody strategies. Drug Discovery Today: Technologies, 42, 85–90. https://doi.org/10.1016/j.ddtec.2024.05.005

Lu, R.-M., Hwang, Y.-C., Liu, I.-J., Lee, C.-C., Tsai, H.-Z., Li, H.-J., & Wu, H.-C. (2020). Development of therapeutic antibodies for the treatment of diseases. Journal of Biomedical Science, 27, Article 1. https://doi.org/10.1186/s12929-019-0592-z

Medscape. (s.d.). Humira (adalimumab): Indications, dosage et effets secondaires. https://francais.medscape.com/voirarticle/3603112_2

Mullard, A. (2020). The antibody pipeline. Nature Reviews Drug Discovery, 19, 748–751. https://doi.org/10.1038/d41573-020-00179-8

Mullard, A. (2024). Bispecific antibodies reach the clinic. Drug Discovery Today, 29(3), 617–620. https://doi.org/10.1016/j.drudis.2024.01.027

Nelson, A. L., Dhimolea, E., & Reichert, J. M. (2010). Development trends for human monoclonal antibody therapeutics. Nature Reviews Drug Discovery, 9(10), 767–774. https://doi.org/10.1038/nrd3229

ProteoGenix. (s.d.). Fully human antibody development services. ProteoGenix. https://www.proteogenix.science/custom-antibody/therapeutic-antibody-services/antibody-discovery/fully-human-antibody-development-services/

Qin, J., Li, K., Li, N., & Yan, F. (2022). Advances in antibody engineering. International Journal of Oncology, 61(5), 1–12. https://doi.org/10.3892/ijo.2022.5302

Reichert, J. M. (2008). Monoclonal antibodies as innovative therapeutics. mAbs, 1(1), 1–15. https://doi.org/10.1016/j.tips.2008.10.001

Sanofi. (2023, 7 mars). Sanofi annonce des résultats positifs pour Dupixent® dans l’urticaire chronique spontanée. https://www.sanofi.com/fr/media-room/communiques-de-presse/2023/2023-03-07-06-00-00-2621670

Silva, D., et al. (2022). Therapeutic antibodies in Brazil: Trends and challenges. Brazilian Journal of Pharmaceutical Sciences, 58. https://doi.org/10.1590/s2175-97902022e20084

Smith, J., et al. (2023). Antibody therapeutics: New frontiers. Frontiers in Immunology, 14, Article 1137069. https://doi.org/10.3389/fimmu.2023.1137069

Walsh, G. (2013). Biopharmaceutical benchmarks. Nature Biotechnology, 31(10), 992–1000. https://doi.org/10.1038/nbt.2704

Weng, Z., et al. (2022). Comprehensive analysis of antibody repertoires. Communications Biology, 5, Article 4129. https://doi.org/10.1038/s42003-022-04129-7

Zhao, Y., & Li, X. (2022). Computational antibody design. Cell Reports Medicine, 3(4), 100–110. https://doi.org/10.1186/s43556-022-00100-4